CClinicalTrials.gg
Sign In
Status unknownNCT03794193Updated May 4, 2022

The Effect of Unfavorable Histological Features on the Oncological Outcomes of Colon Cancer

An observational study in Colon Cancer, sponsored by Peking Union Medical College Hospital. Status unknown. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-05-04.

Sponsored by Peking Union Medical College Hospital · Observational

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,367
Ages
18 Years to 100 Years
Sex
All
01

Study summary

To explore the effect of unfavorable histological features on the clinical outcomes of patients receiving radical resection of colon cancer.

02

Conditions studied

  • Colon Cancer

Browse trials for

03

In context

Colonic Neoplasms

1,432 studies on the registry are indexed under Colonic Neoplasms; 357 are open to participants now.

This study's planned enrollment of 1,367 is above the median of 280 across 349 observational studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Colon cancer patients with or without unfavorable histological features

Inclusion criteria

  1. Age: 18-100 years old;
  2. Postoperative pathology confirmed colon adenocarcinoma;
  3. The tumor is located from the cecum to the sigmoid colon;
  4. No distant organ metastasis;

Exclusion criteria

Exclusion Criteria:

  1. Simultaneous or metachronous multiple primary colorectal cancer;
  2. History of previous malignant tumors (except for completely cured cervical carcinoma in situ or basal cell carcinoma or squamous epithelial skin cancer)
  3. local excision procedure;
  4. palliative resection (R2 resection);
  5. pregnant or lactating women.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,367 participants (estimated)
Patient registry
No

Interventions

  • ProcedureRadical resection of colon cancer

    The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.

    Also known as: Chemotherapy

06

What researchers measure

Primary outcomes

  1. 3-year Disease-free Survival

    The time from the time of surgery to the time of recurrence or death from any cause, calculated on a monthly basis, with the most recent recurrence and metastasis.

    Time frame: Within 3 years after surgery

Secondary outcomes

  1. 3-year Over-all Survival

    The time from the time of surgery to the time of recurrence or death from any cause, calculated on a monthly basis.

    Time frame: Within 3 years after surgery

  2. Postoperative complication rate

    Time frame: Within 30 days after surgery

  3. Postoperative mortality rate

    Time frame: Within 30 days after surgery

  4. Local recurrence rate

    Time frame: Within 3 years after surgery

  5. Distant organ metastasis rate

    Time frame: Within 3 years after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data can be shared with all researchers involved in the study.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03794193
Lead sponsor
Peking Union Medical College Hospital
Collaborators
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, West China Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Peking University First Hospital, Wuhan Union Hospital, China
Responsible party
Sponsor
First posted
Jan 4, 2019
Start date
Jan 1, 2016
Primary completion
Dec 2020
Completion
Dec 2023 (estimated)
Last update
May 4, 2022

Study contacts

Yi Xiao, MD
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Colonic Neoplasms→

Other studies from this sponsor

Peking Union Medical College Hospital

Start the discussion